EIK1001 — Topline data
2H2026
2H2026 Phase 2 data readout NSQSource filing
EIKN biotech catalysts & pipeline
EIKON THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
EIK1005 — Initial data
2H 2026
Initial data from Phase 1/2 study | 2H 2026Source filing
EIK1006 — IND submission
Late 2026
Eikon expects to submit an investigational new drug application (IND) for EIK1006 by the end of 2026.Source filing
EIK1001 — Interim data
1H2027
Second interim analysis to proceed to Ph3 for melanoma study | 1H2027Source filing
EIK1003 — Conference presentation
Oct 23
Eikon will present clinical data from its ongoing Phase 1/2 trial of EIK1003 on Friday, October 23 at the ESMO Congress 2026 in Madrid, Spain.Source filing
EIK1004 — Conference presentation
Oct 23
On Friday, October 23 at the ESMO Congress 2026 in Madrid, Spain, Eikon will also present, for the first time, data from an ongoing Phase 1/2 trial evaluating the safety and efficacy of EIK1004, a selective PARP1 inhibitor designed to penetrate the CNS, for the treatment of patients with ovarian, breast, prostate, and pancreatic cancers ( NCT06907043 ).Source filing
EIK1005 — Conference presentation
Oct 23
Preliminary safety, tolerability and pharmacokinetic data for EIK1005 will be presented on Friday, October 23 at the ESMO Congress 2026 in Madrid, Spain.Source filing
EIK1001 — Conference presentation
Oct 26
Eikon will present comprehensive updated data from TeLuRide-005 ( NCT06246110 ), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with non–small cell lung cancer (NSCLC), on Monday, October 26 at the ESMO Congress 2026 in Madrid, Spain.Source filing